Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$159.69 USD

159.69
4,765,963

+0.16 (0.10%)

Updated Oct 8, 2024 04:00 PM ET

Pre-Market: $159.80 +0.11 (0.07%) 9:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

by Zacks Equity Research

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Intuitive Surgical Stock Declines 0.7% in a Month: Is It Losing Steam?

by Zacks Equity Research

ISRG stock has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. However, the stock has declined in the past month. Let's see if the trend might change.

Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PWV

Derek Lewis headshot

Should Investors Consider High Yield Dividend Stocks?

by Derek Lewis

When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield. But is high yield always the way to go?

Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?

by Zacks Equity Research

JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.

Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus

by Zacks Equity Research

As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.

Why Johnson & Johnson (JNJ) Dipped More Than Broader Market Today

by Zacks Equity Research

Johnson & Johnson (JNJ) concluded the recent trading session at $160.50, signifying a -0.42% move from its prior day's close.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More

by Kinjel Shah

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

Johnson & Johnson (JNJ) closed at $162.78 in the latest trading session, marking a -0.27% move from the prior day.

Kinjel Shah headshot

J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?

by Kinjel Shah

We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.

Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time

by Zacks Equity Research

The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.

Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma

by Zacks Equity Research

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs

by Kinjel Shah

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC

by Zacks Equity Research

With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.

Sundeep Ganoria headshot

Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?

by Sundeep Ganoria

BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises.

Indrajit Bandyopadhyay headshot

ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?

by Indrajit Bandyopadhyay

Intuitive Surgical is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.

Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

Johnson & Johnson (JNJ) closed the most recent trading day at $166.99, moving +0.89% from the previous trading session.

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Kinjel Shah headshot

TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

by Kinjel Shah

Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

by Kinjel Shah

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.

FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

by Zacks Equity Research

With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.